EU Menopause Care: What New Parliament Hearings Mean for Women's Health Policy

The European Parliament has placed menopause care firmly on the EU health policy agenda in August 2026, following a series of hearings that concluded on 21 August 2026. These hearings mark the first time the institution has systematically examined menopause as a cross-border health and workplace equality issue, with Members of the European Parliament (MEPs) calling for a coordinated EU strategy to harmonise treatment access, fund dedicated research, and mandate workplace accommodations across all 27 member states. For the 90% of European women who will experience menopause, this policy shift represents a potential turning point in how midlife health is funded, studied, and supported.

The Current Landscape: Gaps in European Menopause Care

The European Parliament hearings, convened by the Committee on Women's Rights and Gender Equality (FEMM) and the Committee on Public Health (SANT), exposed stark inconsistencies in how EU member states approach menopause. According to testimony presented by the European Institute of Women's Health (EIWH) on 19 August 2026, fewer than half of EU member states have any formal clinical guideline for menopause care, and only three countries (Germany, France, and the Netherlands) offer dedicated menopause clinics within their public health systems.

Data Gaps and Clinical Inconsistencies

Eurostat data from June 2026 reveals that menopause-related healthcare spending across the EU averages just €3.20 per woman aged 45-55 annually, compared with €58 for cardiovascular health in the same demographic. The European Medicines Agency (EMA) reported in its July 2026 pharmacovigilance review that hormone replacement therapy (HRT) prescribing rates vary by a factor of 12 between member states, with Polish women six times less likely to receive HRT than their Swedish counterparts, despite identical clinical presentations.

Dr. Marlene van der Berg, a menopause specialist at Amsterdam UMC who testified before the Parliament on 20 August 2026, stated: "We have the science. We know what works. What we do not have is a mechanism to translate that science into consistent practice. A woman in rural Andalusia and a woman in central Berlin are receiving fundamentally different standards of care for a condition that affects 90% of our population." Her testimony cited a 2025 Eurobarometer survey showing that 68% of European women aged 45-60 had never discussed menopause with a healthcare professional.

Impact on Women: Health, Work, and Equality

The economic case for EU action is substantial. According to the European Commission's Directorate-General for Employment, published in April 2026, women aged 45-55 constitute the fastest-growing segment of the EU workforce, representing 11.2% of all employed persons across the bloc. The same report estimated that untreated menopause symptoms cost the EU economy approximately €42 billion annually in lost productivity, reduced working hours, and premature workforce exit.

Workplace Consequences and Caregiving Burdens

The hearings highlighted a double burden faced by menopausal women: they are frequently simultaneously supporting ageing parents and dependent children, making them the "sandwich generation" of EU caregiving. Eurofound research presented during the hearings showed that 34% of menopausal women in the EU report reducing their working hours due to symptoms, while 17% have declined promotion opportunities. This creates a measurable impact on the EU's gender pay gap, which Eurostat pegged at 12.7% in 2025.

MEP Sandra Ortega Sánchez (Spain, Greens/EFA), who initiated the hearings, told the chamber on 21 August 2026: "Menopause is not a private inconvenience; it is a public policy issue of gender equality, economic sustainability, and healthcare equity. We cannot claim to support women in the workforce while ignoring the biological reality that half the population faces." Her constituent case studies, drawn from a Spanish Ministry of Equality survey of 12,000 women conducted in March 2026, found that 41% of menopausal women had considered leaving their jobs entirely.

The Call to Action: What EU Initiatives are Needed

The parliamentary hearings concluded with a draft resolution, expected to be voted on in the October 2026 plenary session, that outlines five key pillars for EU action. The resolution text, obtained during the hearings, calls for a dedicated EU Research Framework Programme (Horizon Europe) funding stream for menopause, currently absent from the 2025-2027 work programme.

Proposed EU Framework for Menopause Care

Specifically, the resolution asks the European Commission to develop a "European Menopause Care Quality Standard" that would harmonise clinical guidelines, training requirements, and patient access protocols. This standard would be voluntary but tied to EU Structural Fund payments, creating a financial incentive for member states to adopt best practices. The Commission has been asked to report back on feasibility by March 2027.

Additionally, the hearings examined the potential for a European Menopause Research Network, modelled on the European Reference Networks (ERNs) that currently coordinate care for rare diseases. Professor Elena Rossi of the University of Milan, who coordinates the Italian Menopause Registry, testified that such a network could pool data from the estimated 25 million European women currently experiencing perimenopause or menopause, enabling large-scale longitudinal studies that individual nations cannot undertake alone.

Social Impact: Who is Most Affected and What is at Stake

The social impact of inadequate menopause care falls hardest on low-income women and those in rural regions. The European Consumer Organisation (BEUC) submitted evidence to the hearings showing that private menopause clinics across the EU charge between €150 and €350 per consultation, placing them out of reach for the approximately 22% of EU women aged 50-60 who live in households at risk of poverty or social exclusion, according to Eurostat's 2025 EU-SILC data.

Immigrant women and those from ethnic minority backgrounds face additional barriers. A 2025 study from the European Public Health Alliance found that first-generation immigrant women in the EU are 40% less likely to seek help for menopause symptoms due to language barriers, cultural stigma, and unfamiliarity with healthcare navigation. This creates a two-tier system where affluent, urban women access cutting-edge care, while rural, low-income, and minority women suffer silently, often self-medicating with unregulated supplements or enduring symptoms that damage their quality of life for years.

The mental health dimension is equally urgent. The hearings received written evidence from the European Psychiatric Association showing a 28% increase in first-time depression diagnoses among EU women aged 48-53 between 2015 and 2025, a pattern strongly correlated with the hormonal transitions of perimenopause. Without EU-wide education for General Practitioners, many of these women are treated with antidepressants alone, receiving no hormone assessment despite clear clinical guidelines advocating integrated approaches.

Breaking the Stigma: The Role of Awareness and Education

A central theme of the parliamentary hearings was the persistent stigma that prevents open discussion of menopause across EU member states. Dr. Elisabeth Fontaine, a French gynaecologist who led a 2026 awareness campaign for the French Health Ministry, told the Parliament: "We have made enormous progress in destigmatising menopause in France, but the dialogue remains dominated by medical professionals. We need a cultural shift where menopause is discussed in workplaces, in families, and in media with the same seriousness as other significant health transitions."

Country-Level Variations in Awareness

The hearings documented significant national differences in public awareness and professional training. Sweden and Finland have integrated menopause education into standard medical school curricula, while several Southern and Eastern European member states offer no mandatory training whatsoever. A 2025 survey of EU medical schools, cited during the hearings, found that only 12 of 89 responding institutions allocated more than four hours of teaching time to menopause across their entire medical degree programme.

This variation has real consequences. The European health coverage of the hearings reported that Italian women face an average 11-month wait to see a menopause specialist through the national health service, while German women can typically access one within three weeks. The same article highlighted that Swedish women are three times more likely than Polish women to report satisfaction with menopause information provided by their clinician.

Beyond the Parliament: Implementing Change Across Europe

The path from parliamentary resolution to member state implementation is long and uncertain. The European Commission has historically been cautious about intervening in healthcare, which remains a national competence under EU treaties. However, the hearings demonstrated growing support for using the EU's "soft power" mechanisms: research funding, benchmarking exercises, and the open method of coordination.

Early signs are promising. On 24 August 2026, the German Federal Ministry of Health announced it would host a "National Menopause Summit" in November, citing the European Parliament hearings as a direct trigger. The Dutch government has indicated it will use its 2027 EU Council Presidency to advance the menopause agenda, proposing a council conclusion on "Midlife Women's Health and Labour Force Participation." These developments suggest that the Parliament's initiative may catalyse action at national level even before binding EU measures are agreed.

Financial and Structural Barriers

However, significant obstacles remain. The EU's pharmaceutical regulatory framework currently requires menopause treatments to be assessed under general medicines rules, with no specific provisions for long-term safety monitoring in diverse European populations. The hearings heard that the recent EMA review of bioidentical hormone preparations, completed in May 2026, highlighted substantial gaps in post-market surveillance data from Southern and Eastern member states, where these products are increasingly popular but poorly tracked.

Employer engagement will also prove critical. While the EU's 2026 Work-Life Balance Directive already provides some flexibility, it does not explicitly reference menopause-related workplace adjustments. The European Trade Union Confederation (ETUC), which submitted written evidence to the Parliament, has proposed a "Menopause Charter" for EU employers, including temperature control policies, flexible scheduling, and access to private rest spaces. The ETUC estimated that such measures could reduce menopause-related workforce exits by up to 35% based on pilot programmes in Belgian and Danish companies.

Conclusion: A Future of Integrated Menopause Support

The August 2026 European Parliament hearings have shifted the menopause conversation from private suffering to public policy. For the first time, there is a credible pathway toward EU-wide standards for menopause care, dedicated research funding, and workplace protections for the 11% of the EU workforce currently navigating this transition. The connections between menopause and Europe's gender equality commitments, its economic competitiveness, and its demographic sustainability are now established facts in Brussels policy circles, not marginal concerns.

For women across Germany, France, Spain, Italy, the Netherlands, Poland, and every other member state, the coming year will determine whether these hearings translate into tangible improvements. The European Commission's response to the October 2026 resolution vote will be the first critical test, followed by the feasibility report due in March 2027 and the Dutch EU Presidency 12 months later.

The evidence is clear: consistent, accessible, and evidence-based menopause care is achievable across the EU if member states coordinate through shared standards and pooled research. The biological reality of menopause affects half the population. The policy response must finally reflect that reality.

What You Can Do: Practical Steps for EU Women

Book a dedicated menopause consultation: If you are aged 40-60 and have never discussed perimenopause with a healthcare professional, schedule an appointment with your GP or gynaecologist. Come prepared with a symptom diary covering at least two months. Ask specifically about hormone replacement therapy options, cardiovascular risk assessment, and bone density screening, all of which should be standard care under European Society of Endocrinology guidelines.

Check your workplace rights: Under the EU Work-Life Balance Directive, you may be entitled to request flexible working arrangements. While menopause is not explicitly named, symptoms can constitute a disability under the EU Employment Equality Directive if they have a substantial long-term impact. Document workplace adjustments that would help you (temperature control, ventilation, flexible hours) and formally request them. European labour tribunals in France, Germany, and the Netherlands have begun accepting menopause-related claims under these provisions.

Join patient advocacy networks: Contact the European Menopause and Andropause Society (EMAS) or your national menopause organisation (such as the German Menopause Society, the French Gynécologie Sans Frontières menopause network, or the Italian Menopause Registry). These organisations are actively contributing to EU consultations and can amplify your personal experiences into policy evidence.

Participate in research opportunities: If EU research funding is approved under Horizon Europe, large-scale observational studies will need participants. Please consider joining national menopause registries or clinical trial databases. More data from Southern, Eastern, and rural member states is essential to address the current geographic bias in menopause research.

Write to your MEP: With the October 2026 resolution vote approaching and the Commission response due in 2027, constituent pressure is consequential. Email your MEP's office and ask where they stand on the menopause resolution, the research fund, and the proposed standards. This is the most direct mechanism for shaping EU policy between now and the end of 2027.

Baba International Editorial Team

Our editorial team specialises in UK and EU personal finance, health policy, and economic analysis. All content is researched using authoritative sources including the ONS, NHS, Bank of England, ECB, and Eurostat.

Frequently Asked Questions

What exactly did the European Parliament hearings conclude in August 2026?

The hearings concluded with a draft resolution calling for an EU Menopause Care Quality Standard, dedicated Horizon Europe research funding, a European Menopause Research Network, and workplace accommodation guidelines. The resolution is scheduled for a plenary vote in October 2026, with the European Commission required to respond to its recommendations by early 2027.

Is menopause care currently covered by EU health policy?

No. EU treaties assign primary responsibility for healthcare delivery to member states. However, the EU can coordinate research funding, set quality benchmarks through the open method of coordination, and use financial incentives (such as Structural Funds) to encourage adoption of common standards. The current hearings aim to expand these coordination mechanisms specifically for menopause care.

How do menopause rates in Europe compare globally?

Eurostat data from 2025 indicates that approximately 25 million EU women are currently experiencing perimenopause or menopause, with an estimated 1.2 billion women globally projected to be in this stage by 2030, according to World Health Organization projections. European women have longer post-menopausal lifespans than women in most other regions, making the quality of midlife healthcare particularly consequential for EU health systems and pension sustainability.

What financial support is available for menopause treatment in EU countries?

Coverage varies dramatically by member state. France, Germany, and the Netherlands include HRT under standard health insurance with minimal co-payments. Portugal and Ireland provide partial reimbursement, while in Poland and Bulgaria, most menopause treatments require private payment. The proposed EU standard would aim to harmonise these reimbursement approaches and ensure minimum coverage across all member states, regardless of national income levels.

For further reading on related EU health and workplace policy developments, see our coverage of European health equality initiatives and our analysis of the economic impact of women's health gaps.

EU Menopause Care: What New Parliament Hearings Mean for Women's Health Policy